Common Medications Cut Death Risk by 46% in Older Adults During Rehabilitation
Study of 1,890 geriatric patients finds metformin, ACE inhibitors, aspirin and beta-blockers significantly reduce mortality risk.
Summary
A major study of 1,890 geriatric rehabilitation patients found that common medications originally developed for other conditions significantly reduce death risk. Patients taking metformin had 46% lower mortality, while those on ACE inhibitors, aspirin, or beta-blockers had 24-29% lower death rates within one year. Most remarkably, patients using three or more of these drugs together had 41% lower mortality risk. The medications studied—metformin for diabetes, ACE inhibitors for blood pressure, aspirin for heart protection, and beta-blockers for cardiovascular conditions—appear to provide survival benefits beyond their original intended uses, supporting the concept of repurposing existing drugs as anti-aging therapies.
Detailed Summary
This groundbreaking research suggests that common medications you may already be taking could significantly extend your lifespan. The study represents one of the largest investigations into whether existing drugs can serve as anti-aging therapies in real-world clinical settings.
Researchers analyzed 1,890 geriatric rehabilitation patients with an average age of 82.6 years over two years. They examined five potential "gerotherapeutic" drugs: metformin (diabetes medication), ACE inhibitors and ARBs (blood pressure medications), aspirin (blood thinner), beta-blockers (heart medications), and bisphosphonates (bone medications). The team tracked mortality, hospital readmissions, and physical function changes.
The results were striking. Patients taking metformin showed the greatest benefit with 46% lower one-year mortality risk. ACE inhibitors reduced death risk by 29%, aspirin by 26%, and beta-blockers by 24%. Bisphosphonates showed no significant effect. Most importantly, patients taking three or more of these medications simultaneously had 41% lower mortality risk, suggesting potential synergistic effects.
These findings support the emerging field of geroscience, which seeks to repurpose existing medications as longevity interventions. Unlike experimental anti-aging compounds, these drugs have established safety profiles and are already widely prescribed. The mortality benefits appeared independent of the medications' primary therapeutic effects, suggesting they may target fundamental aging processes.
However, this was an observational study, meaning it cannot prove causation. Patients taking these medications may have had better overall healthcare or different baseline health characteristics. Additionally, the study focused on hospitalized elderly patients, so results may not apply to healthier populations. Controlled clinical trials are needed to confirm these promising findings.
Key Findings
- Metformin users had 46% lower one-year mortality risk compared to non-users
- ACE inhibitors, aspirin, and beta-blockers each reduced death risk by 24-29%
- Taking three or more gerotherapeutic drugs together lowered mortality risk by 41%
- Benefits were independent of the drugs' primary therapeutic effects on specific conditions
- No improvements were seen in physical function recovery or hospital readmission rates
Methodology
Longitudinal observational study of 1,890 geriatric rehabilitation inpatients (mean age 82.6 years, 56% female) from the RESORT cohort. Patients were followed for up to two years post-discharge, with mortality, readmission, and functional outcomes tracked. Statistical analysis adjusted for comorbidities using the Charlson Comorbidity Index.
Study Limitations
This observational study cannot establish causation, and patients taking these medications may have had better overall healthcare or different baseline characteristics. The study focused on hospitalized elderly patients, limiting generalizability to healthier populations. Randomized controlled trials are needed to confirm these associations and establish optimal dosing strategies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.